Treatment with PPARδ agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model

Author：                  

Publisher： Spandidos Publications

E-ISSN： 1791-244X|36|3|767-775

ISSN： 1107-3756

Source： International Journal of Molecular Medicine, Vol.36, Iss.3, 2015-01, pp. : 767-775

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Non-alcoholic fatty liver disease

By Smith Briohny W.   Adams Leon A.  

Critical Reviews in Clinical Laboratory Sciences, Vol. 48, Iss. 3, 2011-06 ,pp. : 97-113

Informa Healthcare

Access to resources Recommend Favorite

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study

By Athyros Vasilios G.   Mikhailidis Dimitri P.   Didangelos Triandafillos P.   Giouleme Olga I.   Liberopoulos Evangelos N.   Karagiannis Asterios   Kakafika Anna I.   Tziomalos Konstantinos   Burroughs Andrew K.   Elisaf Moses S.  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 873-883

Informa Healthcare

Access to resources Recommend Favorite

New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)

By Ali Rafeeq   Cusi Kenneth  

Annals of Medicine, Vol. 41, Iss. 4, 2009-01 ,pp. : 265-278

Informa Healthcare

Access to resources Recommend Favorite

Heterogeneity of non‐alcoholic fatty liver disease

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 12, 2015-12 ,pp. : 2498-2500

John Wiley & Sons Inc

Access to resources Recommend Favorite

Non-Alcoholic Fatty Liver Disease in Older People

By  

Gerontology, Vol. 55, Iss. 6, 2009-08 ,pp. : 607-613

Karger

Access to resources Recommend Favorite